Detail akcie Bristol Myers online

Business Summary: Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bristol-Myers Squibb Co revenues decreased 1% to $35.69B. Net income totaled $5.97B vs. loss of $9.02B. Revenues reflect Revlimid segment decrease of 68% to $1.41B, Eliquis segment decrease of 27% to $7.43B, United States segment decrease of 34% to $16.85B, International segment decrease of 28% to $7.08B. Net Income reflects Acquired IPRD decrease of 83% to $2.33B (expense).